Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

We sought to investigate the clinical profile(s) associated with the discontinuation of lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable hepatocellular carcinoma (HCC). This retrospective study enrolled 177 patients with HCC treated with LEN. Independent factors as...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancers (Basel)
Huvudupphovsmän: Shimose, Shigeo, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Okamura, Shusuke, Nakano, Masahito, Suga, Hideya, Kuromatsu, Ryoko, Yamaguchi, Taizo, Kawaguchi, Takumi, Tanaka, Masatoshi, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2020
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7408786/
https://ncbi.nlm.nih.gov/pubmed/32664489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071867
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk